SCHEMBL4374479

SCHEMBL4374479

COc1cc2c(Oc3ccc(Br)cc3F)ncnc2cc1OCCCNC(=O)OC(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.56
ATM Q13315 3/20 0.50
TRPA1 O75762 1/20 0.50
KDR P35968 12/20 0.49
FLT1 P17948 1/20 0.49
FLT4 P35916 1/20 0.49
FLT3 P36888 1/20 0.47
MET P08581 1/20 0.46
EGFR P00533 5/20 0.46
RET P07949 1/20 0.45
KIF5B P33176 1/20 0.45
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC10 Q969S8 2/20 0.45
HDAC11 Q96DB2 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4422588 0.85 FLT4 (0.55) AXLKDRFLT1FLT4FLT3
SCHEMBL4375640 0.82 TRPA1 (0.54) TRPA1KDRFLT1FLT4MET
SCHEMBL4421666 0.81 TRPA1 (0.63) AXLTRPA1KDRFLT1FLT4
SCHEMBL4375675 0.81 TRPA1 (0.63) AXLTRPA1KDRFLT1FLT4
SCHEMBL5911661 0.80 KDR (0.70) KDREGFRHDAC3HDAC4HDAC1
SCHEMBL4374482 0.78 TRPA1 (0.50) TRPA1KDRFLT1FLT4FLT3
SCHEMBL167217 0.78 AXL (0.70) AXLATMFLT3MET
SCHEMBL5911613 0.77 EGFR (0.73) KDRFLT4EGFRHDAC3HDAC4
SCHEMBL1468261 0.77 KDR (0.68) KDRFLT1FLT4EGFRHDAC3
SCHEMBL30279467 0.77 EGFR (0.73) KDRFLT4EGFRHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR AXL 1087/4885ATM 3304/4885TRPA1 2422/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 AXL 645/4885ATM 4215/4885TRPA1 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.